File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A review on trends in development and translation of omics signatures in cancer

TitleA review on trends in development and translation of omics signatures in cancer
Authors
Ma, WeiTang, WenshuKwok, Jamie S.L.Tong, Amy H.Y.Lo, Cario W.S.Chu, Annie T.W.Chung, Brian H.Y.
KeywordsCancer genomics
DNA methylation
Machine learning
Mutational signatures
Transcriptomics
Translational Medicine
Issue Date1-Dec-2024
PublisherElsevier
Citation
Computational and Structural Biotechnology Journal, 2024, v. 23, p. 954-971 How to Cite?
DOI: http://dx.doi.org/10.1016/j.csbj.2024.01.024
AbstractThe field of cancer genomics and transcriptomics has evolved from targeted profiling to swift sequencing of individual tumor genome and transcriptome. The steady growth in genome, epigenome, and transcriptome datasets on a genome-wide scale has significantly increased our capability in capturing signatures that represent both the intrinsic and extrinsic biological features of tumors. These biological differences can help in precise molecular subtyping of cancer, predicting tumor progression, metastatic potential, and resistance to therapeutic agents. In this review, we summarized the current development of genomic, methylomic, transcriptomic, proteomic and metabolic signatures in the field of cancer research and highlighted their potentials in clinical applications to improve diagnosis, prognosis, and treatment decision in cancer patients.
Persistent Identifierhttp://hdl.handle.net/10722/350132

 

DC FieldValueLanguage
dc.contributor.authorMa, Wei-
dc.contributor.authorTang, Wenshu-
dc.contributor.authorKwok, Jamie S.L.-
dc.contributor.authorTong, Amy H.Y.-
dc.contributor.authorLo, Cario W.S.-
dc.contributor.authorChu, Annie T.W.-
dc.contributor.authorChung, Brian H.Y.-
dc.date.accessioned2024-10-21T03:56:21Z-
dc.date.available2024-10-21T03:56:21Z-
dc.date.issued2024-12-01-
dc.identifier.citationComputational and Structural Biotechnology Journal, 2024, v. 23, p. 954-971-
dc.identifier.urihttp://hdl.handle.net/10722/350132-
dc.description.abstractThe field of cancer genomics and transcriptomics has evolved from targeted profiling to swift sequencing of individual tumor genome and transcriptome. The steady growth in genome, epigenome, and transcriptome datasets on a genome-wide scale has significantly increased our capability in capturing signatures that represent both the intrinsic and extrinsic biological features of tumors. These biological differences can help in precise molecular subtyping of cancer, predicting tumor progression, metastatic potential, and resistance to therapeutic agents. In this review, we summarized the current development of genomic, methylomic, transcriptomic, proteomic and metabolic signatures in the field of cancer research and highlighted their potentials in clinical applications to improve diagnosis, prognosis, and treatment decision in cancer patients.-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofComputational and Structural Biotechnology Journal-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCancer genomics-
dc.subjectDNA methylation-
dc.subjectMachine learning-
dc.subjectMutational signatures-
dc.subjectTranscriptomics-
dc.subjectTranslational Medicine-
dc.titleA review on trends in development and translation of omics signatures in cancer-
dc.typeArticle-
dc.identifier.doi10.1016/j.csbj.2024.01.024-
dc.identifier.scopuseid_2-s2.0-85185401827-
dc.identifier.volume23-
dc.identifier.spage954-
dc.identifier.epage971-
dc.identifier.eissn2001-0370-
dc.identifier.issnl2001-0370-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats